



(51) International Patent Classification:

C07D 237/16 (2006.01) *A61K 31/501* (2006.01)
C07D 401/10 (2006.01) *A61P 25/18* (2006.01)
C07D 407/10 (2006.01) *A61P 29/00* (2006.01)
A61K 31/50 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/GB2012/000672

(22) International Filing Date:

21 August 2012 (21.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1114399.7 22 August 2011 (22.08.2011) GB
 1118658.2 27 October 2011 (27.10.2011) GB
 1203533.3 29 February 2012 (29.02.2012) GB

(71) **Applicant** (for all designated States except US): **TAKE-DA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045 (JP).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **FARNABY, William** [GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **FIELDHOUSE, Charlotte** [GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **HAZEL, Katherine** [GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **KERR, Catrina** [GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **KINSELLA, Natasha**

[GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **LIVERMORE, David** [GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **MERCHANT, Kevin** [GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB). **MILLER, David** [GB/GB]; Takeda Cambridge Ltd, 418 Cambridge Science Park, Cambridge CB4 0PA (GB).


(74) **Agents:** **JONES, Nicholas Andrew** et al.; Withers & Rogers LLP, 4 More London Riverside, London SE1 2AU (GB).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title:** PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS



(57) **Abstract:** The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R¹ and R² are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.



Published:

— *with international search report (Art. 21(3))*